Vitrafy Life Sciences Limited Stock: price and insider trades · Australia
Vitrafy Life Sciences Limited: what insiders have been doing
Every trade that managers of Vitrafy Life Sciences Limited disclose to ASX is tracked on this page. 1 insider has disclosed 2 filings since 8 November 2025.
None of the filings is a plain purchase or sale on the open market; they cover grants, option exercises and other movements. Such operations are usually part of compensation schedules, which makes them a weaker signal than an open-market trade.
Compared with its exchange (2,535 companies, median 3 filings), a count of 2 filings is below the norm.
Over the last twelve months, not one insider purchase of Vitrafy Life Sciences Limited stock was filed.
Source: insider filings from ASX. Past trades are no guide to future returns.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2026FY ended June 2026 · cache
- 103,197 shares@ A$2.600.0016% mcap50.0% of flowShareASXISIN AU0000361297ASX:2924-03109544-3A696895
- 103,197 shares@ A$2.600.0016% mcap50.0% of flowShareASXISIN AU0000361297ASX:2924-03109490-3A696884
2 of 2 declarations
About Vitrafy Life Sciences Limited
Vitrafy Life Sciences Limited is a company listed on the ASX, specializing in the life sciences sector. It focuses on developing innovative solutions to enhance health and well-being.